ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
The plan is to advance innovative therapies to drug-resistant cancers
The FDA has determined that the known and potential benefits of the vaccine for the prevention of Covid-19 outweigh the known and potential risks for individuals 18 years of age and older for whom other authorized or approved vaccines are not accessible
While Pregabalin will be manufactured at the Aurangabad facility, Iloperidone will be manufactured at the Goa facility
The drug will be manufactured at the group's formulation facility at SEZ, Ahmedabad
According to the National Institutes of Health, more than six million Americans, most age 65 or older, may have dementia caused by Alzheimer's disease, a brain disorder known to slowly destroy memory and thinking skills
Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
The announcement follows FDA 510(k) clearance of device
Three RFPs now open for qualified researchers through NORD's Jayne Holtzer rare disease research grants program
Subscribe To Our Newsletter & Stay Updated
